AI Article Synopsis
- - The HPV Serology Laboratory is spearheading a global initiative focused on standardizing and harmonizing how serology assays are used to evaluate immune responses to HPV vaccines.
- - This standardization is crucial due to the rise of immunobridging trials that depend on serology data for the approval of new vaccine schedules and formulations.
- - Established in 2017, the initiative aims to facilitate data comparisons across different vaccines and studies, promoting faster adoption of new vaccines and their applications.
Article Abstract
The HPV Serology Laboratory is leading a global partnership initiative aiming for standardization and harmonization of current serology assay platforms being used to assess immune responses to HPV vaccines. Serology standardization is particularly important given the increasing number of immunobridging trials relying on serology data for approval of new vaccine dosing schedules or vaccine formulations. The initiative was established in 2017 to enable comparisons of data between different vaccines and relevant studies as well as expedite the implementation of new vaccines and vaccine indications. The HPV Serology Laboratory has held or attended several meetings with partnering laboratories, including international meetings in 2017, 2018, and 2021.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10309594 | PMC |
| http://dx.doi.org/10.1371/journal.ppat.1011403 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Naturally Acquired Genotype-Specific HPV Seroreactivity and Subsequent HPV Detection Among Heterosexual Partners.
J Med Virol
January 2025
Division of Cancer Epidemiology, McGill University, Montreal, Quebec, Canada.
The protective effect of naturally acquired humoral immunity against human papillomavirus (HPV) infection remains unclear. To investigate the role of infection-induced antibodies on HPV detection in heterosexual partners, we used data from 392 unvaccinated couples (females aged 18-25 years attended up to six visits over 2 years; males aged 17-37 years attended up to two visits 4 months apart) enrolled (2005-2011) in Montreal. Genital and blood samples were HPV DNA genotyped and tested for L1 antibody titers of 14 HPV genotypes.
View Article and Find Full Text PDFSerum Antibodies Against the E5 Oncoprotein from Human Papillomavirus Type 16 Are Inversely Associated with the Infection and the Degree of Cervical Lesions.
Biomedicines
November 2024
Centro de Investigación Sobre Enfermedades Infecciosas, Instituto Nacional de Salud Pública, Cuernavaca 62100, Mexico.
Background: The humoral immune response against human papillomavirus (HPV) has been suggested as a source of biomarkers for the early detection of cervical cancer (CC). Therefore, we aimed to characterize the antibody response against HPV16 E5 in the natural history of cervical cancer and to determine its usefulness as a biomarker of HPV-associated cervical lesions.
Methods: This study was conducted at the Cuautla General Hospital, Morelos, Mexico, with women (18 to 64 years) who agreed to participate.
Natural history of HPV16-E6 serology among cancer-free men in a multicenter longitudinal cohort study.
J Natl Cancer Inst
December 2024
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, U.S.A.
Article Synopsis
- HPV16-E6 antibodies can predict the risk of oropharyngeal squamous cell carcinoma (OPSCC) decades before diagnosis, but their utility for screening is still being studied.
- In a study of nearly 4,000 cancer-free men across Brazil, Mexico, and the U.S., only 0.35% tested positive for HPV16-E6 antibodies, with older age being a significant predictor of seropositivity.
- Among the men who tested positive, most maintained their antibody presence over several years, suggesting that HPV16-E6 seropositivity could serve as a reliable biomarker for tracking HPV-related OPSCC risk.
Quadrivalent HPV (4vHPV) vaccine immunogenicity and safety in women using immunosuppressive drugs due to solid organ transplant.
Front Cell Infect Microbiol
November 2024
Departamento de Infectologia e Medicina Tropical da Faculdade de Medicina da Universidade de Sao Paulo (FMUSP), Sao Paulo, Brazil.
Introduction: Immunocompromised persons are at high risk of persistent Human Papilloma Virus (HPV) infection and associated diseases. Few studies evaluated HPV vaccines in immunocompromised persons. This study aimed to evaluate the quadrivalent HPV vaccine (4vHPV) immunogenicity and safety in solid organ transplant (SOT) recipients, in comparison to immunocompetent women (IC).
View Article and Find Full Text PDFSystematic review and meta-analysis of the association between naturally induced IgG, IgM and neutralising antibodies to HPV16 and newly detected cervical HPV16 infection outcomes.
Sex Transm Infect
November 2024
Department of Social and Preventive Medicine, School of Public Health, Université de Montréal, Montreal, Quebec, Canada.
Article Synopsis
- The study investigates whether naturally induced antibodies to HPV16 help prevent new infections in unvaccinated women, focusing on IgG, IgM, and neutralizing antibodies.
- It found that women with higher levels of HPV16 IgG and neutralizing antibodies had a lower risk of newly detected infections, especially in younger women under 25.
- The results suggest that while these antibodies may offer moderate protection, their effectiveness decreases with age, highlighting important considerations for public health strategies against HPV.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!